WO2018153977A1 - Composition stable de ténofovir alafénamide - Google Patents

Composition stable de ténofovir alafénamide Download PDF

Info

Publication number
WO2018153977A1
WO2018153977A1 PCT/EP2018/054373 EP2018054373W WO2018153977A1 WO 2018153977 A1 WO2018153977 A1 WO 2018153977A1 EP 2018054373 W EP2018054373 W EP 2018054373W WO 2018153977 A1 WO2018153977 A1 WO 2018153977A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
tenofovir alafenamide
component
pharmaceutical
present
Prior art date
Application number
PCT/EP2018/054373
Other languages
English (en)
Inventor
Polona Smrdel
Rok Grahek
Tina TRDAN LUSIN
Original Assignee
Hexal Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexal Ag filed Critical Hexal Ag
Publication of WO2018153977A1 publication Critical patent/WO2018153977A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Definitions

  • the present invention relates to a composition
  • a composition comprising tenofovir alafenamide, a stabilizing agent, preferably an earth alkali salt and/or silicon dioxide, and a pharmaceutical excipient. Further, the invention relates to a method of preparing said composition.
  • the pharmaceutical compositions of the present invention can be used for the treatment and/or prophylaxis of viral infections such as HIV infections.
  • Tenofovir alafenamide is a prodrug of tenofovir, wherein tenofovir is reported to be useful in the treatment of viral infections.
  • the IUPAC name of tenofovir alafenamide is 9-[(R)- 2-[[(S)-[[(S)- 1 -(isopropoxycarbonyl)ethyl]amino]phenoxy- phosphinyl]methoxy]propyl] adenine and the compound is represented by the following chemical structure according to formula (I):
  • tenofovir alafenamide is an antiviral compound useful for the treatment and/or prophylaxis of viral infections including infections caused by DNA viruses, RNA viruses, herpesviruses (e.g. CMV, HSV 1 , HSV 2, VZV), retroviruses, hepadnaviruses (e.g. HBV), papillomavirus, hantavirus, adenoviruses and HIV.
  • the compound is also known under the lab code "GS-7340”.
  • Tenofovir alafenamide may be administered alone or in combination with other antiviral agents to patients in need.
  • Tablets containing tenofovir alafenamide are marketed under the tradename Vemlidy. According to the prescribing information, apart from the pharmaceutical active ingredient the tablets contain croscarmellose sodium, lactose monohydrate, magnesium stearate and microcrystalline cellulose. Further, the tablets are film-coated with a coating containing iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
  • tenofovir alafenamide is also marketed under the tradenames Genvoya (a four-drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide), Odefsey (a three-drug combination of emtricitabine, tenofovir alafenamide and rilpivirine) and Descovy (a two-drug combination of emtricitabine and tenofovir alafenamide).
  • Genvoya a four-drug combination of elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide
  • Odefsey a three-drug combination of emtricitabine, tenofovir alafenamide and rilpivirine
  • Descovy a two-drug combination of emtricitabine and tenofovir alafenamide.
  • the chemical name, empirical formula, molecular weight, and structure of the active ingredient tenofovir alafenamide fumarate in the prescribing information show that the marketed products contain the hemifumarate form of tenofovir alafenamide. Tenofovir alafenamide may occur in free form as well as in the form of acid addition salts, cocrystals and/or crystalline forms.
  • WO 02/008241 A2 discloses crystalline tenofovir alafenamide free base and a tenofovir alafenamide monofumarate (referred to herein as form I) as well as processes for their preparations.
  • form I a tenofovir alafenamide monofumarate
  • Another disclosure of tenofovir alafenamide monofumarate can be found in Example 6 and Figure 2 of WO 2015/040640 A2. According to the latter document, the process for the preparation is similar to the process described in Example 4 of WO 02/008241 A2.
  • WO 2013/025788 Al describes a crystalline hemifumarate form of tenofovir alafenamide.
  • Table 1 stability test of TAF HF and TAF MF
  • TAF HF and TAF MF show significant degradation under stress conditions.
  • Two major degradants were formed, which were identified as PMPA ((R)-9-[2- (phosphonomethoxy)propyl]adenine) and phenyl hydrogen((((i?)-l-(6-amino-0H-purin- 9-yl)propan-2-yl)oxy)methyl)phosphonate.
  • it was an object of the present invention to provide a physically stable pharmaceutical composition i.e. a pharmaceutical composition in which the conversion of the active pharmaceutical ingredient into other polymorphic form(s) is advantageously reduced or prevented.
  • the above objects are unexpectedly achieved by a pharmaceutical composition comprising tenofovir alafenamide, an earth alkali metal salt and/or silicon dioxide, and pharmaceutical excipient, wherein the pharmaceutical composition has a specific water activity.
  • a pharmaceutical composition comprising (A) tenofovir alafenamide, (B) silicon dioxide, magnesium chloride, calcium chloride and/or magnesium sulfate as well as (C) a pharmaceutical excipient, preferably having a water content of less than 3 wt%.
  • a subject of the invention is a pharmaceutical composition comprising
  • composition comprising
  • a further subject of the invention is the method for preparing a dosage form according to the present invention comprising the steps of providing component (A), component (B) and component (C), optionally dry granulating the mixture from step (i) and optionally one or more further pharmaceutical excipient(s) (D),
  • step (i) compressing the mixture from step (i) or the granules from step (ii) and optionally one or more further pharmaceutical excipient(s) (D) to a tablet or
  • step (i) filling the mixture from step (i) or the granules from step (ii) and optionally one or more further pharmaceutical excipient(s) (D) into a capsule.
  • the invention relates to the pharmaceutical composition according to the present invention for use in the treatment and/or prophylaxes of HIV and HBV infections.
  • the pharmaceutical composition of the present invention allows the stabilisation of tenofovir alafenamide.
  • an advantageous composition can be provided which shows, even under harsh conditions, an advantageously reduced amount of degradation product of the active pharmaceutical ingredient.
  • oral dosage form denotes preparations (e.g. tablets) for oral administration, each containing a single dose of one or more active pharmaceutical ingredient(s).
  • tenofovir alafenamide refers to 9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl] amino]phenoxyphosphinyl]methoxy]propyl] adenine according to formula (I) disclosed herein above.
  • a process for the preparation is disclosed in WO 02/008241 A2.
  • the term tenofovir alafenamide as used herein also refers to tenofovir alafenamide in the form of the free base as well as to its pharmaceutically acceptable salts, cocrystals, hydrates, solvates, polymorphs and mixtures thereof.
  • the invention also refers to polymorphs of pharmaceutically acceptable salts or cocrystals of tenofovir alafenamide according to formula (I) or to solvates of salts or hydrates or polymorphs or the like.
  • a pharmaceutically acceptable acid addition salt of tenofovir alafenamide can for example be obtained by the reaction of tenofovir alafenamide with any acid which can form a pharmaceutically acceptable, non-toxic tenofovir alafenamide acid addition salt.
  • Suitable acids can for example be sulfuric acid, phosphoric acid, nitric acid, hydrochloric acid, hydrobromic acid, acetic acid, fumaric acid, succinic acid, maleic acid, citric acid and tartaric acid.
  • the term "chemical stability” means that the sum of all degradation products derived from tenofovir alafenamide is below 2.0%, preferably below 0.5% of the total amount of tenofovir alafenamide subjected to defined conditions. In a preferred embodiment, these conditions are selected from:
  • the term "measured at a temperature in the range of from 20 to 30°C” refers to a measurement under standard conditions.
  • standard conditions mean a temperature in the range of from 20 to 30°C, i.e. at room temperature.
  • Standard conditions can mean a temperature of about 22°C.
  • Standard conditions can also mean a temperature of about 25°C.
  • standard conditions can additionally mean a measurement under 20-80% relative humidity, preferably 30-70% relative humidity, more preferably 40-60% relative humidity and most preferably 50% relative humidity.
  • room temperature refers to a temperature in the range of 20 to 30°C.
  • an earth alkali metal salt is referred to as a salt wherein the cation is an earth alkali metal cation such as magnesium, calcium or barium.
  • the anion is an inorganic anion.
  • An inorganic anion is for example referred to as an anion being substantially free of carbon atoms, wherein carbonate and bicarbonate are exceptions and thus considered as inorganic anions.
  • Further examples of inorganic anions are halogens such as chloride, bromide and iodide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, nitrate, nitrite and the like.
  • the anion can be an organic anion.
  • organic anions examples include acetate and citrate, in particular citrate. Especially preferred is magnesium citrate as organic earth alkali salt.
  • anhydrous refers to a solid wherein no water is coordinated in or accommodated by the crystal structure. However, an anhydrate or a solid in anhydrous form may still comprise residual water due to surface adsorption, solvent inclusions and/or absorption in disordered regions.
  • solvate refers to a solid wherein one or more organic solvent(s) is/are coordinated in or accommodated by the crystal structure.
  • hydrate refers to a solid wherein water is coordinated in or accommodated by the crystal structure.
  • Teenofovir alafenamide hemifumarate refers to the hemifumarate form of tenofovir alafenamide, having a chemical structure wherein about two molecules of tenofovir alafenamide are associated with one molecule of fumaric acid.
  • the tenofovir alafenamide hemifumarate can be a crystalline salt, wherein protons have been transferred from at least some of the fumaric acid molecules to tenofovir alafenamide molecules. Since fumaric acid is a dicarboxylic acid, either one proton (i.e. hydrogen fumarate) or two protons (i.e. fumarate) can be transferred, dependent on the environment.
  • the tenofovir alafenamide hemifumarate can be a cocrystal, wherein substantially no protons have been transferred from fumaric acid molecules to tenofovir alafenamide molecules.
  • the term "tenofovir alafenamide hemifumarate" as used herein refers to a cocrystal.
  • tenofovir alafenamide monofumarate refers to the monofumarate form of tenofovir alafenamide having a chemical structure comprising about one molecule of tenofovir alafenamide per molecule fumaric acid.
  • the tenofovir alafenamide monofumarate can be a crystalline salt, wherein protons have been transferred from at least some of the fumaric acid molecules to tenofovir alafenamide molecules. Since fumaric acid is a dicarboxylic acid, either one proton (i.e. hydrogen fumarate) or two protons (i.e. fumarate) can be transferred, dependent on the environment.
  • the tenofovir alafenamide monofumarate can be a cocrystal, wherein substantially no protons have been transferred from fumaric acid molecules to tenofovir alafenamide molecules.
  • the term "tenofovir alafenamide monofumarate" as used herein refers to a cocrystal.
  • Tenofovir alafenamide monofumarate has a molar ratio of tenofovir alafenamide and fumaric acid typically and preferably in a range of from about 1.0 : 0.7 to 1.0 : 1.3, more preferably in a range of from about 1.0 : 0.8 to 1 : 1.2, most preferably in a range of from about 1.0 : 0.9 to 1 : 1.1, and in particular the molar ratio is about 1.0 : 1.0.
  • the transfer of protons from one molecule to another in a crystal is dependent on the environment. Crystalline salts and cocrystals may be thought of as two ends of a proton transfer spectrum, where the salt has completed the proton transfer at one end and an absence of proton transfer exists for cocrystals at the other end.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising (A) tenofovir alafenamide, (B) earth alkali metal salt and/or silicon dioxide, and (C) pharmaceutical excipient, wherein the pharmaceutical composition has a water activity value of less than 0.15.
  • the earth alkali metal salt is an inorganic earth alkali metal salt.
  • the cation can be an alkali earth metal cation, can preferably a magnesium or calcium cation.
  • the inorganic anion can preferably be a halogen or a sulfate.
  • the inorganic alkali earth metal salt can be magnesium chloride (MgCb), calcium chloride (CaCl 2 ), magnesium sulfate (MgS04) or mixtures thereof, especially magnesium chloride (MgCl 2 ).
  • component (B) can be silicon dioxide, in particular amorphous silica.
  • the silicon dioxide can have a specific surface area of 600 to 1000 m 2 /g, preferably about 800 m 2 /g.
  • the specific surface area is regarded as "BET"-surface area and determined according to Ph. Eur., 6 th edition, Chapter 2.9.26.
  • the silicon dioxide has a density between 0.3 and 0.5 kg/dm 3 .
  • An example of preferred silicon dioxide is available under the tradename Syloid ® , preferably Syloid ® AL-1.
  • silicon dioxide S1O2
  • magnesium chloride MgCl 2
  • calcium chloride CaCl 2
  • magnesium sulfate MgS0 4
  • magnesium chloride (MgCl 2 ), calcium chloride (CaCl 2 ) and/or magnesium sulfate (MgS04) can be present in hydrated form.
  • magnesium chloride (MgCl 2 ) can be present as magnesium chloride hexahydrate (MgCl 2 x6H 2 0).
  • calcium chloride (CaCl 2 ) can be present as calcium chloride dihydrate (CaCl 2 x2H 2 0).
  • Magnesium sulfate (MgS0 4 ) can for example be present as magnesium sulfate heptahydrate (MgS04x7H 2 0).
  • component (B) can be an alkali metal salt, preferably selected from sodium sulfate (Na 2 S04) and sodium acetate (NaOAc) or a zinc salt, preferably ZnS0 4 .
  • the pharmaceutical composition of the present invention further comprises a pharmaceutical excipient (C).
  • a pharmaceutical excipient C
  • Suitbale pharmaceutical excipients are for example disclosed in "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende füre", published by H.P. Fielder, 4 th Edition, and "Handbook of Pharmaceutical Excipients", 3 rd Edition, published by A.H. Kibbe, American Pharmaceutical Association, Washington, USA, and Pharmaceutical Press, London. It is preferred that the pharmaceutical excipient (C) has a water content of less than 3 wt%. It is further preferred that the pharmaceutical excipient (C) has a water content of less than 2.5 wt%, more preferably less than 2.0 wt%.
  • the pharmaceutical excipient (C) has a water content of less than 1.5 wt%.
  • the lower limit of the water content could be e.g. 0.01 wt%, 0.1 wt%, 0.2 wt% or 0.5 wt%.
  • the water content can be preferably determined as described below in the experimental section.
  • the pharmaceutical composition of the present invention has a water activity value of less than 0.15, preferably less than 0.12, in particular less than 0.10. Contrary to the content of water of a substance or composition, the water activity value is a measure for the "active" or “available” water of the substance or composition.
  • the water activity value of a substance or composition can be preferably determined as described below in the experimental section.
  • the present invention relates to an alternative pharmaceutical composition
  • an alternative pharmaceutical composition comprising (A) tenofovir alafenamide, (B) silicon dioxide, magnesium chloride, calcium chloride and/or magnesium sulfate and (C) pharmaceutical excipient.
  • the earth alkali metal salt of component (B) can be one or more specific salt(s) selected from magnesium chloride, calcium chloride and/or magnesium sulfate. As far as these specific salts are concerned, the same applies as described above.
  • Component (C) can be a pharmaceutical excipient to which the same applies as described above. It is preferred that the (C) pharmaceutical excipient has a water content of less than 3.0 wt%, preferably of less than 2.5 wt%, more preferably less than 2.0 wt%, in particular of less than 1.5 wt%. The lower limit of the water content could be e.g. 0.01 wt%, 0.1 wt%, 0.2 wt% or 0.5 wt%.
  • tenofovir alafenamide refers to 9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl] amino]phenoxyphosphinyl]methoxy]propyl] adenine according to above formula (1) as well as to tenofovir alafenamide in the form of the free base as well as to its pharmaceutically acceptable salts, cocrystals, hydrates, solvates, polymorphs and mixtures thereof.
  • component (A) is present in a crystalline form of tenofovir alafenamide fumarate, more preferably in form of tenofovir alafenamide hemifumarate or tenofovir alafenamide monofumarate.
  • component (A) can be tenofovir alafenamide hemifumarate .
  • crystalline tenofovir alafenamide hemifumarate as used herein can be the crystalline form of tenofovir alafenamide hemifumarate disclosed in WO 2013/025788 Al .
  • a polymorphic form can be represented by one or more, preferably at least three, specific diffraction peaks in X-ray powder diffraction (XRPD).
  • Tenofovir alafenamide hemifumarate as disclosed in WO 2013/025788 Al can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (6.9 ⁇ 0.2)°, (8.6 ⁇ 0.2)°, (10.0 ⁇ 0.2)°, (1 1.0 ⁇ 0.2)°, (12.2 ⁇ 0.2)°, (15.9 ⁇ 0.2)°, (16.3 ⁇ 0.2)°, (20.2 ⁇ 0.2)° and (20.8 ⁇ 0.2)° when measured at a temperature in the range of from 20 to 30°C with Cu K-alpha 1)2 radiation having a wavelength of 0.15419 nm.
  • reflection with regards to powder X-ray diffraction as used herein means peaks in an X-ray diffractogram which are caused at certain diffraction angles (Bragg angles) by constructive interference from X-rays scattered by parallel planes of atoms in solid material which are distributed in an ordered and repetitive pattern in a long-range positional order.
  • Such a solid material is classified as crystalline material, whereas amorphous material is defined as solid material which lacks long-range order and only displays short-range order, thus resulting in broad scattering.
  • long-range order e.g.
  • the term "essentially the same" with reference to powder X-ray diffraction means that variabilities in reflection positions and relative intensities of the reflections are to be taken into account.
  • a typical precision of the 2-Theta values is in the range of ⁇ 0.2° 2-Theta, preferably in the range of ⁇ 0.1° 2-theta.
  • a reflection that usually appears at 7.3° 2-Theta for example can appear between 7.1° and 7.5° 2-theta, preferably between 7.2° and 7.4° 2-Theta on most X-ray diffractometers under standard conditions.
  • relative reflection intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, sample preparation and other factors known to those skilled in the art and should be taken as qualitative measure only.
  • the term "substantially pure" with reference to a particular physical form means that the physical form includes at most 20%, preferably at most 10%, more preferably at most 5%, even more preferably at most 3% and most preferably at most 1 wt% of any other physical form of the compound.
  • component (A) can be tenofovir alafenamide monofumarate.
  • Tenofovir alafenamide monofumarate as component (A) can be preferably present in crystalline form.
  • crystalline component (A) can be the crystalline form of tenofovir alafenamide monofumarate form I as described in example 4 of WO 02/08241 A2.
  • This form can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of (5.3 ⁇ 0.1)°, (9.8 ⁇ 0.1)°, (10.4 ⁇ 0.1)°, (15.9 ⁇ 0.1)°, (16.2 ⁇ 0.1)° and (16.6 ⁇ 0.1)° when measured at a temperature in the range of from 20 to 30°C with Cu K-alphai, 2 radiation having a wavelength of 0.15419 nm.
  • crystalline component (A) can be the crystalline form of tenofovir alafenamide monofumarate in form II.
  • Tenofovir alafenamide monofumarate in form II can be prepared by suspending tenofovir alafenamide monofumarate in form I in acetonitrile at room temperature, for example as described in Example 1 of PCT/EP2017/052121 filed on February 1, 2017.
  • Tenofovir alafenamide monofumarate in form II can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • crystalline component (A) can be the crystalline form of tenofovir alafenamide monofumarate in form III.
  • Tenofovir alafenamide monofumarate in form III can be prepared as described in Examples 2 and 8 of PCT/EP2017/052121 filed on February 1, 2017.
  • Tenofovir alafenamide monofumarate in form III can be characterized by having a powder X-ray diffractogram comprising reflections at 2-Theta angles of:
  • the terms "physical form” and “solid form” are used interchangeably herein and refer to any crystalline and/or amorphous phase of a compound.
  • the term “about” means within a statistically meaningful range of a value. Such a range can be within an order of magnitude, typically within 10%, more typically within 5%, even more typically within 1 % and most typically within 0.1 % of the indicated value or range. Sometimes, such a range can lie within the experimental error, typical of standard methods used for the measurement and/or determination of a given value or range.
  • component (A) is present from 5 to 40 wt% based on the total weight of the pharmaceutical composition. More preferably, component (A) can be present from 6.0 to 25 wt%, in particular from 7.0 to 12.0 wt%.
  • the pharmaceutical composition of the present invention comprises tenofovir alafenamide as single active pharmaceutical ingredient.
  • the pharmaceutical composition of the present invention comprises tenofovir alafenamide as active pharmaceutical ingredient in combination with one or more further active pharmaceutical ingredient(s).
  • further active pharmaceutical ingredients are emtricitabine, darunavir, cobicistat, elvitegravir, rilpivirine, efavirenz and dolutegravir.
  • component (A) preferably tenofovir alafenamide monofumarate
  • component (A) can for example be used in the following combination, which includes, but is not limited to, single oral dosage form regimens: (a) emtricitabine / tenofovir alafenamide monofumarate;
  • component (B) is present from 2 to 15 wt% based on the total weight of the pharmaceutical composition. More preferably, component (B) can be present from 2.5 to 12 wt%, even more preferably from 3.0 to 9.0 wt%, in particular from 4.0 to 8.0 wt%.
  • the weight ratio of component (A) to component (B) is from 8: 1 to 1 :3, preferably from 7: 1 to 1 :2, in particular from 6: 1 to 1 :1, especially from 5 : 1 to 2: 1.
  • component (A) preferably tenofovir alafenamide monofumarate
  • the pharmaceutical composition of the present invention further comprises a pharmaceutical excipient (C).
  • a pharmaceutical excipient C
  • a pharmaceutically acceptable excipient is an excipient which is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the tenofovir alafenamide, preferably alafenamide monofumarate, so that any side effects ascribable to the excipient do not vitiate the beneficial effects of the tenofovir alafenamide, preferably alafenamide monofumarate.
  • excipients are for example disintegrants, binders, lubricants, fillers, plasticizers, surfactants and wetting agents, film-forming agents and coating materials, sweeteners, flavoring agents, and coloring agents such as for example pigments.
  • excipients known in the field of pharmaceutical compositions may also be used.
  • the pharmaceutical excipient (C) is a filler.
  • Fillers can be used to increase the bulk volume and weight of a low-dose drug to a limit at which a pharmaceutical dosage form can be formed. Fillers may fulfil several requirements, such as being chemically inert, non-hygroscopic and pharmaceutically acceptable.
  • Examples of fillers according to the present invention include, but are not limited to, kaolin, microcrystalline cellulose, silicated microcrystalline cellulose, lactose such as anhydrous lactose or lactose monohydrate form, sugars, such as dextrose, maltose, saccharose, glucose, fructose or maltodextrine, sugar alcohols, such as mannitol, maltitol, sorbitol, xylitol, powdered cellulose, carrageenan, polyethylene glycol and starch.
  • the filler (C) can preferably be present from 40-90 wt%, more preferably from 42-75 wt%, in particular from 45-65wt%, based on the total weight of the composition.
  • the filler can preferably have a water content of less than 3 wt%, preferably of less than 2.5 wt%, more preferably of less than 2.0 wt%, in particular of less than 1.5 wt%.
  • the lower limit of the water content could be e.g. 0.01 wt%, 0.1 wt%, 0.2 wt% or 0.5 wt%.
  • the filler (C) has a water activity value of from 0.001 to 0.1, preferably from 0.005 to 0.08, more preferably from 0.01 to 0.06. Further, the water activity value of filler (C) can preferably be from 0.005 to 0.07, more preferably from 0.01 to 0.06.
  • component (C) is a filler, more preferably component (C) is microcrystalline cellulose. It is particularly preferred that component (C) is microcrystalline cellulose having the before -mentioned water content.
  • component (C) is a filler, more preferably component (C) is lactose. It is particularly preferred that component (C) is anhydrous lactose. It turned out that the use of a filler, preferably microcrystalline cellulose, preferably having the before -mentioned water content, and/or anhydrous lactose, reduces the degradation of tenofovir alafenamide, in particular of tenofovir alafenamide monofumarate.
  • the pharmaceutical composition of the present invention comprises
  • component (B) 5-40 wt%, more preferably 6-25 wt%, in particular 7-12 wt% of component (A), 2-15 wt%, more preferably 3.0-9.0 wt%, in particular 4.0-8.0 wt% of component (B),
  • component (C) 40-90 wt%, more preferably 42-75 wt%, in particular 45-65 wt% of component (C).
  • the pharmaceutical composition of the present invention can comprise one or more further pharmaceutical excipient(s) (D).
  • pharmaceutical excipient (C) the same applies as to pharmaceutical excipient (C), with the proviso that pharmaceutical excipient (C) and one or more further pharmaceutical excipient(s) (D) are different.
  • pharmaceutical excipient (C) is a filler
  • the one or more further pharmaceutical excipient(s) (D) can for example be disintegrants, lubricants, surfactants, glidants, binders, film-forming agents and coating materials, plasticizers and/or coloring agents.
  • Disintegrants are compounds which enhance the ability of the dosage form, preferably the ability of the tablet, to break into smaller fragments when in contact with a liquid, preferably water. Disintegrants can be present for example in an amount of 0 to 10 wt%, preferably in an amount of 0.5 to 5 wt% based on the total weight of the composition.
  • Suitable disintegrants according to the present invention include, but are not limited to, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose (crosslinked carboxymethyl cellulose) sodium, cross-linked polyvinylpyrrolidone, crospovidone (cross-linked povidone, a synthetic cross-linked homopolymer of N-vinyl-2-pyrrolidone), alginic acid, micro crystalline cellulose (such as refined wood pulp derived from alpha cellulose), hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, polacrillin potassium, sodium alginate, sodium starch glycolate, partially hydrolysed starch, sodium carboxymethyl starch, and starch.
  • Lubricants generally can be regarded as substances which are suitable to reduce friction, such as static friction, sliding friction and rolling friction.
  • lubricants reduce the shearing forces occurring on the borderline between tablet and mould, especially the sliding friction found during tablet pressing between the punch moving up and down in the die and the die wall on the one hand and between the edge of the tablet and the die wall on the other hand.
  • Lubricants can be present for example in an amount of 0 to 5 wt%, preferably in an amount of 0.5 to 2.5 wt% based on the total weight of the composition.
  • Suitable lubricants according to the present invention include, but are not limited to, glyceryl monostearate, calcium stearate, magnesium stearate, mineral oil, stearic acid, fumaric acid, sodium stearyl fumarate, zinc stearate and polyethylene glycol, in particular magnesium stearate.
  • Suitable surfactants have the tendency of adsorbing at surfaces and interfaces and thereby reducing the surface tension between the phases.
  • Suitable surfactants according to the present invention include, but are not limited to, heptadecaethylene oxycetanol, lecithins, sorbitol monooleate, polyoxyethylene sorbitol monooleate, polyoxy- ethylene stearate, polyoxyethylen sorbitan monolaurate, benzalkonium chloride, nonoxynol 10, oxtoxynol 9, polysorbates, for example polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80, sorbitan monopalmitate, sodium salts of fatty alcohol sulfates, such as sodium lauryl sulfate, sodium dodecylsulfate, sodium salts of sulfosuccinates, such as sodium dioctylsulfosuccinate, partial esters of fatty acids with alcohols
  • Glidants can be used to improve the flowability. Suitable glidants are for example colloidal silicon dioxide, talcum or mixtures thereof. Glidants can be present in an amount of 0 to 8 wt%, preferably in an amount of 0.1 to 3 wt% based on the total weight of the composition.
  • Binders ensure that tablets and granules can be formed with required mechanical strength, and give volume to low active dose tablets. Binders can be present in an amount of 0 to 15 wt%, preferably in an amount of 3 to 10 wt% based on the total weight of the composition.
  • Suitable binders according to the present invention include, but are not limited to, hydroxypropyl cellulose, hypromellose (hydroxy- propyl methylcellulose, HPMC), acacia, alginic acid, carboxymethyl cellulose, ethyl cellulose, methylcellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, polyvinyl alcohol, polyacrylates, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, compressible sugar, ethyl cellulose, gelatin, liquid glucose, methylcellulose, polyvinyl pyrrolidone and pregelatinized starch.
  • Suitable film-forming agents and coating materials according to the present invention include, but are not limited to, liquid glucose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose (hypromellose, HPMC), methylcellulose, ethyl cellulose, cellulose acetate phthalate, shellac, polyvinylpyrrolidone, copolymers of vinyl pyrrolidone and vinyl acetate such as Kollidon® VA64 BASF, copolymers of acrylic and/or methacrylic acid esters with trimethyl- ammonium methyl acrylate, copolymers of dimethylamino-methacrylic acid and neutral methacrylic acid esters, polymers of methacrylic acid or methacrylic acid esters, copolymers of acrylic acid ethylester and methacrylic acid methyl ester and copolymers of acrylic acid and acrylic acid methylester.
  • liquid glucose hydroxyethyl cellulose, hydroxypropyl cellulose,
  • Suitable plasticizers according to the present invention include, but are not limited to, polyethylene glycol, diethyl phthalate and glycerol. Preference is given to polyethylene glycol.
  • Suitable coloring agents according to the present invention include, but are not limited to, pigments, inorganic pigments, FD&C Red No. 3, FD&C Red No. 20, FD&C Yellow No. 6, FD&C Blue No. 2, D&C Green No. 5, D&C Orange No. 5, D&C Red No. 8, caramel, ferric oxide red, ferric oxide yellow and titanium dioxide.
  • microcrystalline cellulose is a particular hydrolyzed cellulose, which can be used as a filler, binder and/or disintegrating material in tablet production, dependent on formulation context and concentration.
  • terms like “disintegrant”, “binder”, “lubricant”, “filler”, “plasticizer”, “surfactant”, “wetting agent”, “film-forming agent”, “coating material”, “sweetener”, “flavoring agent” and “coloring agent” are primarily functional definitions and that the structural characterizations provided above are given so as to more easily allow identification of suitable excipients.
  • the pharmaceutical composition of the invention be preferably present in an oral doasage form.
  • the oral solid dosage form of the present invention is preferably a compressed or a non-compressed dosage form.
  • the oral solid dosage form of the present invention is a granule, a capsule, for example a capsule filled with granules, a sachet, a pellet, a dragee, a lozenge, a troche, a pastille, or a tablet, such as an uncoated tablet, a coated tablet, an effervescent tablet, a soluble tablet, a dispersible tablet, an orodispersible tablet, a tablet for use in the mouth, a chewable tablet or an extrudate.
  • the oral dosage form is a capsule or tablet, preferably a tablet.
  • another subject of the present invention is an oral dosage form, preferably a tablet, comprising the composition of the present invention as described above and below.
  • the oral dosage form is a tablet
  • the tablet can preferably be coated, more preferably film-coated.
  • film coatings that do not affect the release of the active agent(s) and film coatings affecting the release of the active agent(s) can be employed with tablets according to invention.
  • the film coatings that do not affect the release of the active agent(s) are preferred.
  • Preferred examples of film coatings which do not affect the release of the active ingredient can be those including poly(meth)acrylate, methylcellulose (MC), hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), polyvinylpyrrolidone (PVP), polyvinylalcohol (PVA) and mixtures thereof. More preferred is hydroxypropyl methylcellulose (HPMC). These polymers can have a weight-average molecular weight of 10,000 to 150,000 g/mol. In a preferred embodiment the film can have a thickness of 2 ⁇ to 150 ⁇ , preferably 10 to 100 ⁇ , more preferably 20 to 60 ⁇ .
  • the preferred coating may comprise a film-forming agent and one or more of the following: lubricant, surfactant, glidant, pigment and water.
  • the dosage form of the present invention is packed by a suitable packaging material.
  • the packaging material preferably reduces or prevents water exchange between the pharmaceutical composition of the present invention and the environment.
  • suitable blister pack materials can be used.
  • the blister pack may comprise a cavity or pocket, preferably containing a thermoformed plastic. This usually has as a backing a lidding seal containing an aluminum and/or plastic foil. Further, if the composition is in form of a granulate, suitable sachets can be used.
  • the pharmaceutical composition or the dosage form of the present invention is packed by a material having a water vapor permeability of 0.001 to 0.15 g/m day at 38°C/5%/90% RH, preferably of 0.01 to 0.12 g/m day at 38°C/5%/90% RH, in particular 0.05 to 0.10 g/m7day at 38°C/5%/90% RH, wherein said water vapor permeability is determined according to ASTM F1249-13.
  • a Permatran-W Model 3/33 device is used. The measurement is preferably carried out at 38°C.
  • the packaging material can preferably be selected from polyvinylchloride (PVC), polyvinylidene chloride (PVDC), polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET) polystyrol (PS), polyamide and alumina or combinations thereof.
  • PVDC polyvinylchloride
  • PE polyvinylidene chloride
  • PP polypropylene
  • PET polyethylene terephthalate
  • PS polystyrol
  • the packing material comprises layered sheets, which can be thermoformed, containing one or more layers.
  • the packing material can be a composite material, e.g. co-extruded composite material, e.g. a polyamide-alumina-polyvinyl chloride composite material, which is also referred to as Nylon ® - Alu-PVC.
  • the packaging material has a thickness of 1 ⁇ to 1 mm.
  • the thermoformed plastic pocket preferably has a thickness of 100 to 1000 ⁇ , more preferably of 150 to 800 ⁇ .
  • the backing foil usually has a thickness of 10 to 150 ⁇ , more preferably of 15 to 100 ⁇ .
  • the packed dosage form of the present invention also contains a desiccant, such as silica gel bags and/or molecular sieves.
  • a desiccant such as silica gel bags and/or molecular sieves.
  • step (ii) optionally dry granulating the mixture from step (i) and optionally one or more further pharmaceutical excipient(s) (D),
  • step (iii) compressing the mixture from step (i) or the granules from step (ii) and optionally one or more further pharmaceutical excipient(s) (D) to a tablet or filling the mixture from step (i) or the granules from step (ii) and optionally one or more further pharmaceutical excipient(s) (D) into a capsule.
  • components (A), (B) and (C) are provided.
  • components (A), (B) and (C) and optionally one or more further excipient(s) (D), preferably a disintegrant can be blended.
  • a premix containing components (A) and (B) can be formed by blending and sieving these components.
  • a second, preferably sieved premix comprising component (C) and preferably one or more further excipient(s) (D), preferably a disintegrant, can be added.
  • Sieving can be preferably carried out with a sieve having a mesh size of 25 to 1000 ⁇ , preferably 50 to 800 ⁇ , especially 100 to 600 ⁇ .
  • the resulting mixture of components (A) to (C) and optionally one or more further excipient(s) (D), preferably a disintegrant can preferably be blended in order to provide a composition having a homogenous distribution of the corresponding mixture.
  • Blending can be carried out with conventional mixing devices, e.g. in a free-fall mixer. Blending can be carried out e.g. for 1 minute to 30 minutes, preferably for 2 minutes to less than 10 minutes.
  • the mixture from step (i) and optionally one or more further excipient(s) (D) can be dry-granulated.
  • “Dry” is usually understood to mean that the step is carried out in the absence of a liquid, in particular in the absence of water.
  • “Granulating” is generally understood to mean the formation of relatively coarse or granular aggregate material as a powder by assembling and/or aggregating finer powder particles (agglomerate formation or build-up granulation) and/or the formation of finer granules by breaking up coarser aggregates (disintegration or break-down granulation). Dry granulation can preferably be carried out by using pressure or temperature.
  • granulating the mixture from step (i) can be performed for example by "slugging", using a large heavy-duty rotary press and breaking up the slugs into granulates with a hammer mill or by roller compaction, using for example roller compactors by Powtec or Alexanderwerk. The granuls are then optionally screened.
  • step (iii) the mixture of step (i) or the granules of step (ii) and optionally further excipients (D), preferably a lubricant, can preferably be compressed into a tablet.
  • Compressing the mixture of step (i) or the granules from step (ii) into a tablet can preferably be carried out by compressing said formulation on a rotary press.
  • the main compression force can range from 1 to 50 kN, preferably from 3 to 40 kN, more preferably from 4 to 20 kN.
  • the resulting tablets can have a hardness of 50 to 220 N, more preferably of 60 to 190 N, particularly preferably of 70 to 180 N, more preferably of 80 to 170 N, wherein the hardness can be measured according to Ph. Eur. 6.0, Chapter 2.9.8.
  • the mixture of step (i) or the granules of step (ii) and optionally further excipients (D) can be filled into a capsule.
  • the method of the present invention can preferably comprise a step (iv), in which the tablets from step (iii) can preferably be film coated, wherein film coatings such as Opadry II can be used.
  • the method of the present invention can preferably comprise a step (iv), in which the tablets from step (iii) or step (iv) can be packaged.
  • the materials as described above are used.
  • steps (i), (ii) and (iii) can be performed under non-humid conditions. In particular, these steps can be performed at a temperature of from 0°C to 30°C, preferably 10°C to 25°C. Further, said process is preferably performed at 0 to 40% RH or less, preferably at 5 to 30% RH. The same conditions can be chosen for optional steps (iv) and (v).
  • the dosage form, preferably the tablet, of the invention preferably has a content uniformity, i.e. a content of active agent(s) which lies within the concentration of 90 to 1 10%), preferably 95 to 105%, especially preferred of 98 to 102% of the average content of the active agent(s).
  • the "content uniformity" is determined with a test in accordance with Ph. Eur., 6.0, Chapter 2.9.6. According to that test, the content of the active agent of each individual tablet out of 20 tablets must lie between 90 and 1 10%>, preferably between 95 and 105%, especially between 98 and 102% of the average content of the active agent(s). Therefore, the content of the active agent in each tablet of the invention differs from the average content of the active agent by at most 10%, preferably at most 5% and especially at most 2%.
  • the resulting tablet preferably has a friability of less than 5%, particularly preferably less than 2%, especially less than 1 %.
  • the friability is determined in accordance with Ph. Eur., 6.0, Chapter 2.9.7.
  • the friability of tablets generally refers to tablets without coating.
  • the present invention relates to a method for treating and/or preventing HIV and HBV infections, comprising administering to a subject in need thereof a therapeutically effective amount of the compound of the invention, in particular a compound according to formula (I) where the residues are defined as above, or the pharmaceutical composition of the invention.
  • a therapeutically effective amount of the compound of the invention in particular a compound according to formula (I) where the residues are defined as above, or the pharmaceutical composition of the invention.
  • the same explanations e.g. regarding combination of possible embodiments
  • the treatment of HIV infections is especially preferred.
  • the invention shall be illustrated by the following examples.
  • PXRD was performed with a PANalytical X'Pert PRO diffractometer equipped with a theta/theta coupled goniometer in transmission geometry, Cu-Kalphal ,2 radiation (wavelength 0.15419 nm) with a focusing mirror and a solid state PIXcel detector.
  • Diffractograms were recorded at a tube voltage of 45 kV and a tube current of 40 mA, applying a stepsize of 0.013° 2-theta with 40s per step (255 channels) in the angular range of 2° to 40° 2-theta at ambient conditions.
  • a typical precision of the 2-theta values is in the range of ⁇ 0.2° 2-Theta, preferably of ⁇ 0.1° 2-theta.
  • the diffraction peak of crystalline tenofovir alafenamide monofumarate form II that appears for example at 7.3° 2-Theta can appear in the range of from 7.1 to 7.5° 2-theta, preferably in the range of from 7.2 to 7.4° 2-Theta on most X-ray diffractometers under standard conditions.
  • XRPD and PXRD are used interchangeably herein.
  • the following measurement parameters can be used:
  • Hygrometer chamber Rotronic AW-VC and hygrometer BT-RS 1
  • the sample dish was filled with the specimen and the sample dish was placed in the measuring chamber which had been thermostated to 25 ⁇ 1°C. Then, the measuring chamber was sealed. When equilibrium of the relative humidity was established (trend indication disappears), the corresponding value was determined.
  • dry conditions 60°C in a closed vial for 7 days
  • wet conditions 60°C with addition of 10 ⁇ , of water in a closed vial for 7 days
  • tablets containing present component (B) show significantly less impurities than tablets without said component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition comprenant du ténofovir alafénamide, un agent stabilisant, de préférence un sel alcalino-terreux et/ou du dioxyde de silicium, et un excipient pharmaceutique. En outre, l'invention concerne un procédé de préparation de cette composition. Les compositions pharmaceutiques de la présente invention peuvent être utilisées dans le traitement et/ou la prophylaxie d'infections virales telles que les infections par le VIH.
PCT/EP2018/054373 2017-02-24 2018-02-22 Composition stable de ténofovir alafénamide WO2018153977A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157917.0 2017-02-24
EP17157917 2017-02-24

Publications (1)

Publication Number Publication Date
WO2018153977A1 true WO2018153977A1 (fr) 2018-08-30

Family

ID=58185340

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/054373 WO2018153977A1 (fr) 2017-02-24 2018-02-22 Composition stable de ténofovir alafénamide

Country Status (1)

Country Link
WO (1) WO2018153977A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (fr) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration
WO2002084241A1 (fr) 2001-04-17 2002-10-24 G.D Societa' Per Azioni Procede et unite destines a envelopper un article dans une feuille de materiau d'enveloppage thermoplastique
WO2004064846A1 (fr) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions et methodes de polytherapie antivirale
WO2005084670A1 (fr) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Formulation pharmaceutique
WO2013025788A1 (fr) 2011-08-16 2013-02-21 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
WO2013115916A1 (fr) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Polythérapie comprenant le gs-7340 et le cobicistat destinée à être utilisée dans le traitement d'infections virales
WO2015028875A2 (fr) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir et un comprimé monolithique comprenant du darunavir et du ritonavir
WO2015040640A2 (fr) 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
CN105237571A (zh) * 2014-11-28 2016-01-13 成都苑东药业有限公司 9-[(r)-2-[[(s)-[[(s)-1-(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
WO2016108205A1 (fr) * 2015-01-03 2016-07-07 Mylan Laboratories Limited Procédés de préparation d'hémifumarate de ténofovir alafénamide amorphe et d'un prémélange de ce composé
WO2017004244A1 (fr) * 2015-06-30 2017-01-05 Gilead Sciences, Inc. Formulations pharmaceutiques comprenant du ténofovir et de l'emtricitabine

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008241A2 (fr) 2000-07-21 2002-01-31 Gilead Sciences, Inc. Promedicaments a base d"analogues nucleotidiques de phosphonate et leurs methodes de selection et d"elaboration
WO2002084241A1 (fr) 2001-04-17 2002-10-24 G.D Societa' Per Azioni Procede et unite destines a envelopper un article dans une feuille de materiau d'enveloppage thermoplastique
WO2004064846A1 (fr) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions et methodes de polytherapie antivirale
WO2005084670A1 (fr) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Formulation pharmaceutique
WO2013025788A1 (fr) 2011-08-16 2013-02-21 Gilead Sciences, Inc. Hémifumarate de ténofovir alafénamide
WO2013115916A1 (fr) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Polythérapie comprenant le gs-7340 et le cobicistat destinée à être utilisée dans le traitement d'infections virales
WO2015028875A2 (fr) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Forme pharmaceutique unitaire comprenant de l'emtricitabine, du ténofovir, du darunavir et du ritonavir et un comprimé monolithique comprenant du darunavir et du ritonavir
WO2015040640A2 (fr) 2013-09-20 2015-03-26 Laurus Labs Private Limited Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
CN105237571A (zh) * 2014-11-28 2016-01-13 成都苑东药业有限公司 9-[(r)-2-[[(s)-[[(s)-1-(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐
WO2016108205A1 (fr) * 2015-01-03 2016-07-07 Mylan Laboratories Limited Procédés de préparation d'hémifumarate de ténofovir alafénamide amorphe et d'un prémélange de ce composé
WO2017004244A1 (fr) * 2015-06-30 2017-01-05 Gilead Sciences, Inc. Formulations pharmaceutiques comprenant du ténofovir et de l'emtricitabine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.H. KIBBE: "Handbook of Pharmaceutical Excipients, 3rd ed.", AMERICAN PHARMACEUTICAL ASSOCIATION
H.P. FIELDER: "Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete, 4th ed.", .
VITALIJ K. PECHARSKY; PETER Y. ZAVALIJ: "Fundamentals of Powder Diffraction and Structural Characterization of Materials", 2003, KLUWER ACADEMIC PUBLISHERS, pages: 3

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111686082A (zh) * 2019-03-11 2020-09-22 苏州特瑞药业有限公司 一种富马酸磷丙替诺福韦制剂及其制备方法
CN111419811A (zh) * 2020-05-20 2020-07-17 北京华睿鼎信科技有限公司 一种富马酸替诺福韦艾拉酚胺组合物

Similar Documents

Publication Publication Date Title
JPWO2008069262A1 (ja) 安定性が改善されたフィルムコーティング製剤
AU2017237469B2 (en) Storage stable composition comprising rifaximin alpha
CA2874779A1 (fr) Composition pharmaceutique d'entecavir, et procede de fabrication
WO2018153977A1 (fr) Composition stable de ténofovir alafénamide
KR20190045286A (ko) 로수바스타틴 및 에제티미브를 포함하는 제약 조성물 및 그의 제조 방법
TW201542212A (zh) 包括恩曲他濱、泰諾福韋、地瑞那韋與利托那韋的單位劑量形式以及包括地瑞那韋與利托那韋的單體錠劑
CA3013161C (fr) Forme de dosage orale comprenant du rifaximine sous forme beta
WO2018041281A1 (fr) Composition pharmaceutique comprenant de la rosuvastatine et de l'ézétimibe et son procédé de préparation
WO2019073062A1 (fr) Comprimé contenant du valsartan et du sacubitril
WO2011010316A1 (fr) Compositions pharmaceutiques d'irbésartan
US10961235B2 (en) Crystalline form of masitinib
JP2022532540A (ja) アキシチニブを含有する医薬組成物
KR20210096162A (ko) 의약 조성물
KR102308227B1 (ko) 수니티닙을 함유하는 경구용 정제 조성물
EP2554164B1 (fr) Préparation pharmaceutique à base d'ibuprofène et de codéine à stabilité améliorée
US20150111909A1 (en) Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
EP4188337A1 (fr) Préparation contenant du dexkétoprofène et du tramadol et procédé de fabrication associé
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
JP5321454B2 (ja) 医薬錠剤の製造法
EP2769712A1 (fr) Formulation pharmaceutique comportant des agglomérats d'inhibiteur DPP-IV et des particules d'inhibiteur DPP-IV

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18707023

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18707023

Country of ref document: EP

Kind code of ref document: A1